The Schall Law Firm Investigates ARS Pharmaceuticals Inc. And Shareholders Are Invited To JoinAccesswire • 08/17/24
The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc. And Affected Investors Are Encouraged To JoinAccesswire • 08/16/24
The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc. And Harmed Investors Are Encouraged To JoinAccesswire • 08/15/24
ARS Pharmaceuticals Inc. Is Being Investigated By The Schall Law Firm, And Affected Investors Are Urged To Engage In DialogueAccesswire • 08/15/24
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Begin DiscussionsAccesswire • 08/14/24
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Initiate DialogueAccesswire • 08/13/24
ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call TranscriptSeeking Alpha • 08/12/24
ARS Pharmaceuticals Inc Is Under The Schall Law Firm's Probe And Affected Investors Are Encouraged To Begin ConversationsAccesswire • 08/09/24
ARS Pharmaceuticals Receives FDA Approval of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including AnaphylaxisGlobeNewsWire • 08/09/24
ARS Pharmaceuticals Inc Is Being Investigated By The Schall Law Firm And Impacted Investors Are Urged To Initiate DialogueAccesswire • 08/08/24
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm, And Impacted Investors Are Encouraged To Initiate DialogueAccesswire • 08/07/24
ARS Pharmaceuticals to Participate in the 2024 Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/07/24
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/24
ARS Pharmaceuticals Inc Investigated By The Schall Law Firm And Impacted Investors Urged To Engage In DialogueAccesswire • 08/06/24
ARS Pharmaceuticals Provides Business Highlights and Reports Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/06/24
ARS Pharmaceuticals, Inc. (SPRY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 08/01/24
ARS Pharmaceuticals Inc Is Under Investigation By The Schall Law Firm And Impacted Investors Are Encouraged To Initiate DialoguesAccesswire • 07/19/24
The Schall Law Firm Is Investigating ARS Pharmaceuticals Inc And Urges Affected Investors To Start ConversationsAccesswire • 07/18/24
ARS Pharmaceuticals Inc Is Under Examination By The Schall Law Firm, Impacted Investors Are Encouraged To Initiate DialoguesAccesswire • 07/17/24
The Schall Law Firm Urges Affected Investors To Start Conversation, ARS Pharmaceuticals Inc Is Under ScrutinyAccesswire • 07/16/24
ARS Pharmaceuticals Inc Under Investigation By The Schall Law Firm Encouraging Impacted Investors To Initiate DialogueAccesswire • 07/15/24